UNLABELLED: This study investigated whether the reference background above which a residual mass is considered positive in the International Harmonization Project criteria should be modified for early (18)F-FDG PET evaluation. METHODS: In 92 patients with newly diagnosed diffuse large B-cell lymphoma, the maximal standardized uptake value (SUVmax) was measured on post-cycle 2 PET in the most intense residual mass (or, in the case of negative PET findings, in the area of most intense tumor uptake before therapy), in the mediastinal blood pool (MBP) and the liver, as potential reference background tissues. RESULTS: With MBP as a reference (SUVmax, 2.0 ± 0.6), PET was unable to distinguish early responders from nonresponders. In contrast, with liver as a reference (SUVmax, 2.5 ± 0.7), 2-y progression-free survival was significantly different between patients with PET-negative findings (81.8% [95% confidence interval, 71%-93%]) and patients with PET-positive findings (51.8% [95% confidence interval, 35%-69%], P = 0.003). CONCLUSION: When assessing early response, particularly in risk-adapted therapeutic trials, it seems preferable to refer to a background tissue (liver) with a higher level of uptake than that of current international criteria (MBP) which were designed for end-of-treatment evaluation.
UNLABELLED: This study investigated whether the reference background above which a residual mass is considered positive in the International Harmonization Project criteria should be modified for early (18)F-FDG PET evaluation. METHODS: In 92 patients with newly diagnosed diffuse large B-cell lymphoma, the maximal standardized uptake value (SUVmax) was measured on post-cycle 2 PET in the most intense residual mass (or, in the case of negative PET findings, in the area of most intense tumor uptake before therapy), in the mediastinal blood pool (MBP) and the liver, as potential reference background tissues. RESULTS: With MBP as a reference (SUVmax, 2.0 ± 0.6), PET was unable to distinguish early responders from nonresponders. In contrast, with liver as a reference (SUVmax, 2.5 ± 0.7), 2-y progression-free survival was significantly different between patients with PET-negative findings (81.8% [95% confidence interval, 71%-93%]) and patients with PET-positive findings (51.8% [95% confidence interval, 35%-69%], P = 0.003). CONCLUSION: When assessing early response, particularly in risk-adapted therapeutic trials, it seems preferable to refer to a background tissue (liver) with a higher level of uptake than that of current international criteria (MBP) which were designed for end-of-treatment evaluation.
Authors: Shadi A Esfahani; Pedram Heidari; Elkan F Halpern; Ephraim P Hochberg; Edwin L Palmer; Umar Mahmood Journal: Am J Nucl Med Mol Imaging Date: 2013-04-09
Authors: Emmanuel Itti; Michel Meignan; Alina Berriolo-Riedinger; Alberto Biggi; Amanda F Cashen; Pierre Véra; Hervé Tilly; Barry A Siegel; Andrea Gallamini; René-Olivier Casasnovas; Corinne Haioun Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-07 Impact factor: 9.236
Authors: Andrea Gallamini; Sally F Barrington; Alberto Biggi; Stephane Chauvie; Lale Kostakoglu; Michele Gregianin; Michel Meignan; George N Mikhaeel; Annika Loft; Jan M Zaucha; John F Seymour; Michael S Hofman; Luigi Rigacci; Alessandro Pulsoni; Morton Coleman; Eldad J Dann; Livio Trentin; Olivier Casasnovas; Chiara Rusconi; Pauline Brice; Silvia Bolis; Simonetta Viviani; Flavia Salvi; Stefano Luminari; Martin Hutchings Journal: Haematologica Date: 2014-03-21 Impact factor: 9.941
Authors: Rahul Mehta; Kejia Cai; Nishant Kumar; M Grace Knuttinen; Thomas M Anderson; Hui Lu; Yang Lu Journal: Technol Cancer Res Treat Date: 2016-09-06